Long-term effects of calcineurin inhibitor conversion to mycophenolate mofetil on renal function after liver transplantation

Liver Transplantation

Volumn 13, Issue 7, 2007, Pages 1004-1010

  Créput, Caroline ^a,b   Blandin, Frederique ^b   Deroure, Benjamin ^a   Roche, Bruno ^b   Saliba, Faouzi ^b   Charpentier, Bernard ^a,b   Samuel, Didier ^b   Durrbach, Antoine ^a,b  

^a BICÊTRE HOSPITAL   (France)

^b HÔPITAL PAUL BROUSSE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CALCINEURIN INHIBITOR; CORTICOSTEROID DERIVATIVE; CREATININE; CYCLOSPORIN A; LYMPHOCYTE ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS;

ACUTE GRAFT REJECTION; ADJUVANT THERAPY; ADULT; ALCOHOL LIVER CIRRHOSIS; ALCOHOL LIVER DISEASE; AMYLOIDOSIS; ARTICLE; CHRONIC GRAFT REJECTION; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DIARRHEA; DOSE KIDNEY FUNCTION RELATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL TOXICITY; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY FUNCTION; LEUKOCYTE COUNT; LEUKOPENIA; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LONG TERM CARE; MALE; NEPHROTOXICITY; OPTIMAL DRUG DOSE; OUTCOME ASSESSMENT; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RISK FACTOR; SIDE EFFECT; TREATMENT DURATION; VIRUS HEPATITIS;

ADRENAL CORTEX HORMONES; ADULT; AGED; CYCLOSPORINE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 34547459972     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.21170     Document Type: Article

References (34)

1. Bennett WM. Insights into chronic cyclosporine nephrotoxicity. Int J Clin Pharmacol Ther 1996;34:515-519.
2. Ojo AO, Held PJ, Port FK, Wolfe RA, Leichtman AB, Young EW, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003;349:931-940.
3. Zaltzman JS, Pei Y, Maurer J, Patterson A, Cattran DC. Cyclosporine nephrotoxicity in lung transplant recipients. Transplantation 1992;54:875-878.
4. Goldstein DJ, Zuech N, Sehgal V, Weinberg AD, Drusin R, Cohen D. Cyclosporine-associated end-stage nephropathy after cardiac transplantation: incidence and progression. Transplantation 1997;63:664-668.
5. Bach JF, Feutren G, Noel LH, Hannedouche T, Landais P, Timsit J, et al. Factors predictive of cyclosporine-induced nephrotoxicity: the role of cyclosporine blood levels. Transplant Proc 1990;22:1296-1298.
6. Azoulay D, Lemoine A, Dennison A, Gries JM, Dolizy I, Castaing D, et al. Incidence of adverse reactions to cyclosporine after liver transplantation is predicted by the first blood level. Hepatology 1993;17:1123-1126.
7. O'Grady JG, Forbes A, Rolles K, Calne RY, Williams R. An analysis of cyclosporine efficacy and toxicity after liver transplantation. Transplantation 1988;45:575-579.
8. Gonwa TA, Mai ML, Melton LB, Hays SR, Goldstein RM, Levy MF, et al. End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment. Transplantation 2001;72:1934-1939.
9. Fisher NC, Nightingale PG, Gunson BK, Lipkin GW, Neuberger JM. Chronic renal failure following liver transplantation: a retrospective analysis. Transplantation 1998;66:59-66.
10. Pawarode A, Fine DM, Thuluvath PJ. Independent risk factors and natural history of renal dysfunction in liver transplant recipients. Liver Transpl 2003;9:741-747.
11. Pillebout E, Nochy D, Hill G, Conti F, Antoine C, Calmus Y, et al. Renal histopathological lesions after orthotopic liver transplantation (OLT). Am J Transplant 2005;5:1120-1129.
12. Gallagher MP, Hall B, Craig J, Berry G, Tiller DJ, Eris J. A randomized controlled trial of cyclosporine withdrawal in renal-transplant recipients: 15-year results. Transplantation 2004;78:1653-1660.
13. Ruiz JC, Campistol JM, Grinyo JM, Mota A, Prats D, Gutierrez JA, et al. Early cyclosporine a withdrawal in kidney-transplant recipients receiving sirolimus prevents progression of chronic pathologic allograft lesions. Transplantation 2004;78:1312-1318.
14. Neff GW, Montalbano, M, Slapak-Green G, Berney T, Bejarano PA, Joshi A, et al. A retrospective review of sirolimus (Rapamune) therapy in orthotopic liver transplant recipients diagnosed with chronic rejection. Liver Transpl 2003;9:477-483.
15. Neff GW, Ruiz P, Madariaga JR, Nishida S, Montalbano M, Meyer D, et al. Sirolimus-associated hepatotoxicity in liver transplantation. Ann Pharmacother 2004;38:1593-1596.
16. Abramowicz D, Del Carmen Rial M, Vitko, S, del Castillo D, Manas D, Lao M, et al. Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen: results of a five-year, prospective, randomized study. J Am Soc Nephrol 2005;16:2234-2240.
17. Dudley C, Pohanka. E, Riad H, Dedochova J, Wijngaard P, Sutter C, et al. Mycophenolate mofetil substitution for cyclosporine a in renal transplant recipients with chronic progressive allograft dysfunction: the "creeping creatinine" study. Transplantation 2005; 79:466-475.
18. Hazzan M, Labalette M, Copin MC, Glowacki F, Provot F, Pruv FR, et al. Predictive factors of acute rejection after early cyclosporine withdrawal in renal transplant recipients who receive mycophenolate mofetil: results from a prospective, randomized trial. J Am Soc Nephrol 2005;16:2509-2516.
19. Fortin MC, Raymond MA, Madore F, Fugere JA, Paquet M, St-Louis G, et al. Increased risk of thrombotic microangiopathy in patients receiving a cyclosporin-sirolimus combination. Am J Transplant 2004;4:946-952.
20. Pelle G, Xu Y, Khoury N, Mougenot B, Rondeau E. Thrombotic microangiopathy in marginal kidneys after sirolimus use. Am J Kidney Dis 2005;46:1124-1128.
21. Sollinger HW. Mycophenolate mofetil. Kidney Int Suppl 1995;52:S14-S17.
22. Francois H, Durrbach A, Amor M, Djeffal R, Kriaa F, Paradis V, et al. The long-term effect of switching from cyclosporin A to mycophenolate mofetil in chronic renal graft dysfunction compared with conventional management. Nephrol Dial Transplant 2003;18:1909-1916.
23. Kasiske BL, Chakkera HA, Louis TA, Ma JZ. A meta-analysis of immunosuppression withdrawal trials in renal transplantation. J Am Soc Nephrol 2000;11:1910-1917.
24. Herrero JI, Quiroga J, Sangro B, Girala M, Gomez-Manero N, Pardo F, et al. Conversion of liver transplant recipients on cyclosporine with renal impairment to mycophenolate mofetil. Liver Transpl Surg 1999;5:414-420.
25. Schlitt HJ, Barkmann A, Boker KH, Schmidt HH, Emman-Ouilidis N, Rosenau J, et al. Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: a randomised controlled study. Lancet 2001;357:587-591.
26. Reich DJ, Clavien PA, Hodge EE. Mycophenolate mofetil for renal dysfunction in liver transplant recipients on cyclosporine or tacrolimus: randomized, prospective, multicenter pilot study results. Transplantation 2005;80:18-25.
27. Koch R, Graziadei I, Shulz F, Nachbaur K, Konigsrainer A, Margreiter R, et al. Long term efficacy and safety of mycophenolate mofetil in liver transplant recipients with calcineurin inhibitor-induced renal dysfunction. Transpl Int 2004;17:518-524.
28. Flechner SM, Goldfarb D, Modlin C, Feng J, Krishnamurthi V, Mastroianni B, et al. Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine. Transplantation 2002;74:1070-1076.
29. Pescovitz MD, Govani M. Sirolimus and mycophenolate mofetil for calcineurin-free immunosuppression in renal transplant recipients. Am J Kidney Dis 2001;38:S16-S21.
30. Pageaux GP, Rostaing L, Calmus Y, Duvoux C, Vanlemmens C, Hardgwissen J, et al. Mycophenolate mofetil in combination with reduction of calcineurin inhibitors for chronic renal dysfunction after liver transplantation. Liver Transpl 2006;12:1755-1760.
31. Stewart SF, Hudson M, Talbot D, Manas D, Day CP. Mycophenolate mofetil monotherapy in liver transplantation. Lancet 2001;357:609-610.
32. Khanna A, Plummer M, Bromberek C, Bresnahan B, Hariharan S. Expression of TGF-beta and fibrogenic genes in transplant recipients with tacrolimus and cyclosporine nephrotoxicity. Kidney Int 2002;62:2257-2263.
33. Matl I, Vildicky O, Voska L, Lodererova A, Vitko S. The effect of different immunosuppressive regimens on TGF-beta1 expression in kidney transplant patients. Transpl Int 2005;18:668-671.
34. Ciancio G, Miller J, Gonwa TA. Review of major clinical trials with mycophenolate mofetil in renal transplantation. Transplantation 2005;80:S191-S200.